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PURPOSE. The purpose of this study was to investigate the use of imaging biomarkers in
published clinical trials (CTs) in ophthalmology and its eventual changes during the past 10
years.
METHODS. We sampled from published CTs in the fields of cornea, retina, and glaucoma
between 2005–2006 and 2015–2016. Data collected included year of publication, phase,
subspecialty, location, compliance with Consolidated Standards for Reporting Trials, impact
factor, presence and use of imaging biomarkers (diagnostic, prognostic and predictive;
primary and secondary surrogate endpoints), and use of centralized reading centers.
RESULTS. We included 652 articles for analysis, equally distributed in three timeframes (2005–
2006, 2010–2011, and 2015–2016), mainly reporting phase IV CTs and trials on procedures
(42.2% and 35.4%, respectively). Imaging biomarkers were included in 46.3% of the analyzed
CTs and their use significantly increased over time (P < 0.05). Optical coherence tomography
was the most frequently used device (27.7%), whereas diagnostic biomarkers and secondary
surrogate endpoints were the most frequent biomarker types (19.5% and 22.5%, respectively).
Early-phase CTs showed an increase in the use of biomarkers for patient selection and
stratification over time (P < 0.05), but not in the use of imaging surrogate endpoints (P ¼
0.90). Only 3 of 59 (5.1%) of phase III CTs included primary surrogate imaging endpoints,
whereas secondary surrogate imaging endpoints were present in 50.8% of these trials (P <
0.001). Retinal CTs had the highest prevalence for each type of imaging biomarker (P <
0.001). Reading centers were used in 52 of 302 CTs (17.2%), with no significant time-related
increase.
CONCLUSIONS. Imaging biomarkers are increasingly used in published CTs in ophthalmology.
Additional efforts, including centralized reading centers, are needed to improve their
validation and use, allowing a wider use of these tools as primary surrogate endpoints in
phase III CTs.
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The National Institutes of Health Biomarkers DefinitionsWorking Group defined biomarker as ‘‘a characteristic that
is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention.’’1 More than 10 years
ago, in the white paper titled ‘‘Innovation or Stagnation:
Challenge and Opportunity on the Critical Path to New Medical
Products,’’2 the Food and Drug Administration recognized the
critical role of biomarkers in drug development.
At present, there is broad consensus among researchers and
regulatory agencies regarding the importance of biomarkers to
translate scientific concepts into diagnostic and therapeutic
approaches and technologies.3 They represent an essential set of
tools for accelerating basic science, drug discovery, and medical
product development as well as improving clinical care.3
Biomarkers are generally used for two main indications in
clinical research. First, to select and stratify the study
population (diagnostic, prognostic, and predictive biomarkers)
and second, to replace true clinically relevant endpoints
(surrogate endpoints) predicting the clinical benefit or harm
of interest.1,4,5
The use of biomarkers as surrogate endpoints in very early
phases of clinical trials (CTs) to provide proofs of concept is of
obvious utility. However, their inclusion in phase III CTs, where
potential erroneous decisions based on invalid surrogate
endpoints may have broad public health consequences, may
pose specific and important challenges.1,6,7
Medical imaging is increasingly used for screening, diagno-
sis, prognosis, evaluating the natural history of disease, or
monitoring therapeutic efficacy. An imaging biomarker specif-
ically uses a characteristic that is objectively observed and
measured using an imaging device. The potential advantages of
this approach are the chance to minimize subjective bias and
inaccuracy as a result of unclear measurements, the ability to
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reveal subtle subclinical features or changes, and the oppor-
tunity to have blinded, standardized, and centralized evaluation
of the images.8–11
The past 2 decades have seen a revolution in ophthalmic
imaging, with a near exponential rise in peer-reviewed
publications relating to clinical applications of new imaging
modalities.12 More important, this revolution has now reached
CT design in ophthalmology.11 Thus, we hypothesized that
increased usage of imaging biomarkers in ophthalmic clinical
research has occurred during the past 10 years. The purpose of
this observational retrospective study was to verify this
hypothesis, analyzing the use of imaging biomarkers in
published CTs in ophthalmology and its relative utility during
the past decade.
METHODS
We searched Medline through PubMed for CTs on cornea,
glaucoma, and retina published in three different time periods
from 2005 to 2016. Using filter tools provided by the website,
we selected ‘‘Clinical trial’’ OR ‘‘Randomized controlled trial’’
as article type; ‘‘from 2005/07/01 to 2006/06/30,’’ ‘‘from 2010/
07/01 to 2011/06/30,’’ and ‘‘from 2015/07/01 to 2016/06/30’’
as publication dates; and ‘‘Cornea OR Glaucoma OR Retina’’ as
keywords. Two investigators (DM, MS) independently analyzed
the full text of each paper and assessed the inclusion and
exclusion of trials on the basis of topic (related to cornea,
glaucoma, or retina), of article type (adherent to the World
Health Organization definition of Clinical Trial),13 and of
language (we included English-language papers only). Dis-
agreements were settled by discussion with a third investigator
(EV).
Data collected for each included article consisted of the
following features: Digital Object Identifier (DOI) of the article,
publication timeframe (2005–2006, 2010–2011 or 2015–2016),
phase (I/II, III, IV, or trials on procedures), subspecialty
(cornea, glaucoma, or retina), location (geographical area of
the coordinating site), compliance with Consolidated Stan-
dards for Reporting Trials (CONSORT) guidelines14 (yes if >12
items were fully reported; no if <12 items were fully reported),
and impact factor (impact factor of the journal in which the
study was published).15
Moreover, articles were analyzed to detect the use of
imaging biomarkers in general (yes or no), imaging diagnostic
biomarkers (yes or no), imaging prognostic biomarkers (yes or
no), imaging predictive biomarkers (yes or no), imaging
surrogate primary endpoints (yes or no), and imaging surrogate
secondary endpoints (yes or no) and to assess the use of a
centralized reading center (RC). Biomarker types were defined
on the basis of the Food and Drug Administration–National
Institutes of Health BEST Resource.5
Statistical analysis was conducted with commercial software
(SPSS for Windows, version 21.0; SPSS Sciences, Chicago, IL,
USA). Categorical data were expressed as ‘‘ratios (percentag-
es),’’ impact factor as mean 6 standard deviation. Changes
over the three timeframes were analyzed by linear-by-linear
association trend test. Percentages were compared by v2 test
(with appropriate number of degrees of freedom, depending
on contingency table size), and the impact factor was
compared by Mann-Whitney U test (between two groups) or
by Kruskal-Wallis test (more than three groups). The a level
(type I error) was set at 0.05.
RESULTS
The Medline search provided 1130 articles (367, 388, and 375
in 2005–2006, 2010–2011, and 2015–2016, respectively). After
detailed assessment of article methodology, we included 652
papers for analysis (190, 231, and 231 in 2005–2006, 2010–
2011, and 2015–2016, respectively; Table 1). The 478 excluded
articles included 70 that were out of scope, 332 studies other
than clinical trials, and 76 written in languages other than
English.
The percentage of phase IV CTs and trials on procedures
(275 of 652 [42.2%] and 231 of 652 [35.4%], respectively) was
significantly higher than phase I/II or III trials (87 of 652
[13.3%] and 59 of 652 [9.0%], respectively); P < 0.001.
Comparing the clinical trial phase distribution over the
three timeframes studied, we found a progressive increase in
phase III CTs (2 of 190 [1.1%] vs. 19 of 231 [8.3%] vs. 38 of 231
[16.4%]), and a progressive decrease in phase IV CTs (108 of
190 [56.8%] vs. 92 of 231 [40.0%] vs. 75 of 231 [32.3%]), in
2005–2006, 2010–2011, and 2015–2016, respectively; P <
0.001.
No difference in the number of included articles was found
when grouping the articles on the basis of subspecialty: 203 of
652 (31.1%) vs. 208 of 652 (31.9%) vs. 241 of 652 (37.0%),
respectively, for cornea, glaucoma, and retina; P ¼ 0.14.
Retinal CTs significantly increased in 2010–2011 and 2015–
2016 (95 of 231, 41.3%, and 90 of 231, 38.8%) compared to
2005–2006 (56 of 190, 29.5%); P < 0.05 in both cases.
Retinal studies included most of the phase III CTs (50 of 59
[84.7%]), and the percentage of phase III CTs in retina
progressively increased over time from 1 of 56 (1.8%) in
2005–2006 to 16 of 95 (16.8%) in 2010–2011, to 33 of 90
(36.7%) in 2015–2016; P < 0.001 (Table 2).
Phases I/II and III were minimally represented in cornea
and glaucoma subspecialties (20 of 203 [9.8%] and 11 of 208
[5.3%], respectively). Trials on procedures and phase IV studies
were the most frequent, respectively, in cornea (123 of 203
[60.6%]; P < 0.001) and glaucoma (135 of 208 [64.9%]; P <
0.001) subspecialties (Tables 3, 4).
Grouping the articles on the basis of geographical regions,
91.9% of published CTs were from North America (204 of 652,
31.3%), Europe (228 of 652, 35.0%), and Asia (167 of 652,
25.6%). CTs from Asia progressively increased from 2005–
2006, to 2010–2011, and to 2015–2016 (34 of 190 [17.9%], 52
of 231 [22.6%], and 81 of 231 [34.9%], respectively); P <
0.001.
The percentage of articles compliant with CONSORT
guidelines (393 of 652 [60.3%]) did not show a significant
progressive change over time: 99 of 190 (52.1%) in 2005–2006,
158 of 231 (68.4%) in 2010–2011, and 136 of 231 (58.9%) in
2015–2016; P ¼ 0.24. The mean impact factor of journals
publishing the included CTs progressively increased from 2.08
6 1.28 in 2005–2006 to 3.28 6 4.90 in 2010–2011, and to 3.34
6 4.30 in 2015–2016, P < 0.001. The impact factor of
CONSORT compliant articles was significantly higher (3.55 6
4.92 vs. 2.04 6 1.27); P < 0.001.
In this analysis, the published CTs including imaging
biomarkers were 302 of 652 (46.3%). Tables 5 and 6 report,
respectively, the most commonly used imaging devices and the
imaging parameters most frequently used as biomarkers.
Over the three timeframes, we found a significant time-
related increase of imaging biomarkers usage: 74 of 190
(38.9%) in 2005–2006, 113 of 231 (48.9%) in 2010–2011, and
115 of 231 (49.8%) in 2015–2016, P < 0.05. A similar
significant trend was also found limiting the analysis to imaging
biomarkers used for patient selection and stratification
(including predictive, diagnostic, and prognostic): 31 of 190
(16.3%) in 2005–2006, 55 of 231 (23.8%) in 2010–2011, and 67
of 231 (29.0%) in 2015–2016; P < 0.01 (Table 7).
Early-phase CTs (phases I/II and III) showed a significant
increase over time in the use of biomarkers for patient
selection and stratification (including predictive, diagnostic
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and prognostic): 5 of 14 (35.7%) in 2005–2006, 30 of 64
(46.9%) in 2010–2011, and 42 of 68 (61.8%) in 2015–2016; P <
0.05. The same analysis performed on surrogate imaging
endpoints (including both primary and secondary endpoints)
showed no significant growth over the three timeframes; P ¼
0.90.
Although 30 of 59 (50.8%) of phase III CTs used secondary
surrogate imaging endpoints, we found only 3 of 59 (5.1%)
phase III CTs including primary surrogate imaging endpoints:
two on retina16,17 (macular thickness by optical coherence
tomography [OCT] and lesion enlargement by fundus auto-
fluorescence) and one on glaucoma18 (iris color photography).
Conversely, phase IV CTs included primary surrogate imaging
endpoints in 75 of 275 (27.2%) cases; P < 0.001.
Furthermore, grouping the trials on the basis of subspecial-
ty, the retina field demonstrated a higher percentage of CTs
that included imaging biomarkers, as compared to both cornea
and glaucoma (186 of 241 [77.2%] vs. 75 of 203 [36.9%] vs. 41
of 208 [19.7%], respectively); P < 0.001. Repeating the same
analysis, considering each type of biomarker separately, retinal
CTs showed the highest prevalence of imaging biomarkers in
any case (Table 8).
Centralized RCs were used in 52 of 302 CTs (17.2%), with
no significant time-related increase: 8 of 74 (10.8%) vs. 25 of
113 (22.1%) vs. 19 of 115 (16.5%), respectively, in the three
timeframes; P¼0.13. We found a significant higher presence of
RCs in retina CTs (48 of 186, 25.8%) when compared with the
other subspecialties (0 of 75 and 4/41 [9.8%], respectively, in
cornea and glaucoma); P < 0.001. Grouping by phases, RCs
were used in 21 of 48 (43.8%) of phase III CTs, 14 of 64
(21.9%) of phase I/II, 17 of 108 (15.7%) of phase IV, and 0 of 82
in CTs on procedures; P < 0.001.
The mean impact factor related to articles reporting CTs
including imaging biomarkers was significantly higher (3.60 6
5.57) when compared with those without imaging biomarkers
(2.40 6 1.42); P < 0.001. Similarly, research articles including
RCs were published in journals with higher impact factors
(5.94 6 8.83 vs. 3.11 6 4.49; P < 0.05).
CONSORT-compliant reports showed a significantly higher
percentage of trials including at least one imaging biomarker
(212 of 393 [53.9%] vs. 90 of 259 [34.7%]); P < 0.001.
Interestingly, CTs on retina showed the best CONSORT
compliance (173 of 241 [71.8%]) when compared with the
two other subspecialties (117 of 203 [57.6%] and 103 of 208
[49.5%] for cornea and glaucoma, respectively; P < 0.001).
DISCUSSION
The inclusion of imaging biomarkers in ophthalmic clinical
research shows great promise and, on the basis of our data,
these tools are included in almost half of the ophthalmic
clinical trials published in the past 10 years. We found a
TABLE 1. Features of Included Published Clinical Trials
Assessed Features 7/2005–6/2006 7/2010–6/2011 7/2015–6/2016 Total
Number of papers 190 231 231 652
Phases
I–II 12 45 30 87
III 2 19 38 59
IV 108 93 74 275
Trials on procedures 68 74 89 231
Subspecialty
Cornea 66 65 72 203
Glaucoma 68 71 69 208
Retina 56 95 90 241
Geographical area
North America 55 80 69 204
South America 9 10 6 25
Europe 86 79 63 228
Asia 34 52 81 167
Oceania 5 5 3 13
Africa 1 4 10 15
CONSORT compliance
Yes 99 158 136 393
No 91 72 96 259
Impact factor 2.08 6 1.28 3.28 6 4.90 3.34 6 4.30 2.95 6 3.97
CONSORT, Consolidated Standards for Reporting Trials.
TABLE 2. Main Features of Published Retinal Clinical Trials
Retina 2005–2006 2010–2011 2015–2016 Total
Number of papers 56 95 90 241
Phases
I–II 5 36 24 65
III 1 16 33 50
IV 36 26 18 80
Trials on procedures 14 17 15 46
TABLE 3. Main Features of Published Corneal Clinical Trials
Cornea 2005–2006 2010–2011 2015–2016 Total
Number of papers 66 65 72 203
Phases
I–II 7 7 2 16
III 0 0 4 4
IV 19 22 19 60
Trials on procedures 40 36 47 123
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significantly increasing use of imaging biomarkers in general as
tools for patient selection and stratification (mostly diagnostic
biomarkers) and as secondary surrogate endpoints. The large
use of imaging biomarkers requires efforts aimed to their
standardization, rigorous validation, and adequate use as part
of high-quality and well-designed clinical studies as well as the
utility of centralized RCs.
For early-phase studies, we reported a high increase in the
percentage of CTs including imaging biomarkers, other than
surrogate endpoints, in the past 10 years. Given regulatory and
broad public health implications, the inclusion of primary
surrogate imaging endpoints in phase III CTs has particular
challenges, starting from the need for appropriate validation
and qualification processes. As recently discussed by Wagner
and Atkinson,6 validation is the process of assessing the assay
and its measurement performance characteristics and deter-
mining the range of conditions under which the assay will give
reproducible and accurate data. Qualification, essential for
surrogate endpoints, is the ‘‘fit for purpose’’ process aimed to
demonstrate not only the link between a biomarker and a
biological process but also that, ‘‘within the stated context of
use, a biomarker can be relied upon to have a specific
interpretation and application in drug development and
regulatory review.’’4,19
Furthermore, the use of imaging data as a primary endpoint
in CTs requires particular attention to the need for trial-specific
imaging process standards and for centralized, blinded imaging
interpretation by RCs.11
Centralized RCs guarantee collection of high-quality, stan-
dardized, and unbiased imaging data that are uniform across
different clinical sites and masked to any clinical information.20
Our data showed that CTs including imaging biomarkers
assessed by centralized RCs were published in journals with a
higher impact factor, suggesting that these research articles
might obtain broader consideration. Moreover, RCs were
mostly used in phase III CTs, which have more stringent
regulatory requirements. Our failure to demonstrate a time-
related increase in the use of RCs suggests the need for huge
commitment to the improvement of imaging biomarkers usage
in clinical research.
TABLE 4. Main Features of Published Glaucoma Clinical Trials
Glaucoma 2005–2006 2010–2011 2015–2016 Total
Number of papers 68 71 69 208
Phases
I–II 0 2 4 6
III 1 3 1 5
IV 53 45 37 135
Trials on procedures 14 21 27 62
TABLE 5. Most Commonly Used Imaging Devices by Subspecialty
Retina, n ¼ 241 Cornea, n ¼ 203 Glaucoma, n ¼ 208
OCT, 152 (63.1) Corneal topography,
29 (14.3)
Color photography,
14 (6.7)
FAG, 82 (34.0) AS-OCT, 16 (7.9) OCT, 13 (6.3)
Color photography,
19 (7.9)
In vivo confocal
microscopy, 13 (6.4)
Doppler ultrasound,
7 (3.4)
Autofluorescence,
9 (3.7)
External color
photography, 6 (2.9)
GDx, 5 (2.4)
Data are expressed as number of observed cases (percentage). OCT,
optical coherence tomography; FAG, fluorescein angiography; AS-OCT,
anterior segment optical coherence tomography; GDx, scanning laser
polarimetry. T
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Major efforts are needed to avoid the potential consequenc-
es of biomarker misuse or of the choice of invalid surrogate
endpoints (ranging from the approval of a therapy favorably
affecting the surrogate but not the clinical endpoint21 to the
failure of trials because of underpowering or poor patients
selection22). On the other hand, it is essential to allow imaging
biomarkers to play a central role in supporting new drugs
development and approval. Our data highlight these concerns,
showing a persistent almost total lack of primary surrogate
imaging endpoints in phase III CTs to date.
In our analysis, phase IV CTs showed a significantly higher
presence of primary surrogate imaging endpoints (27.2%). This
finding may be because of the very high utility of this approach
in postmarketing trials, which require less stringent validation
and allow a less risky and more pioneering use of biomarkers
to demonstrate their proof of concept. However, standardiza-
tion and validation are also important in phase IV CTs because,
as stated by Ioannidis in the controversial article titled ‘‘Why
Most Published Research Findings Are False,’’23 ‘‘the greater
the flexibility in designs, definitions, outcomes, and analytical
modes in a scientific field, the less likely the research findings
are to be true.’’23
The subspecialty-based analysis revealed that retinal CTs
had the highest prevalence of every type of imaging biomarker,
mainly because of the wide use of OCT (included in 27.7% of
all the analyzed CTs and in 63.1% of CTs on retina). Fujimoto
and Swanson recently highlighted the dramatic growth in OCT-
related publications during the past years, indicating the extent
of scientific and clinical progress due to this technology.24
Moreover, in the past 10 years, the pivotal role of OCT imaging
in the development of anti-angiogenic therapies for the
treatment of macular diseases provided a remarkable example
of the potentials of synergy between imaging technologies and
pharmaceutical research in ophthalmology.25
Another interesting result is that articles reporting retinal
CTs showed the most frequent use of RCs and the highest
CONSORT compliance. Given the well-known suboptimal
adherence to these standards in published trials,26–28 we
arbitrarily defined as compliant the articles fully reporting
more than one half of the items included in the CONSORT
checklist.14 Although not a direct measure of the intrinsic
quality of a study, reporting quality provides the reader with
useful tools for the evaluation of its validity.
The present study provides new preliminary information on
ophthalmic implications of a hot topic in clinical research.
However, our study has some limitations. The methodology
used for search and inclusion of articles is partially arbitrary
and provided a relatively small sample of articles, particularly
of phase III trial reports. Moreover, as it is based on already
published and indexed reports, this study does not include the
most recently designed CTs and might not fully reflect the very
last state of imaging use in clinical research.
In conclusion, this study shows a large use of imaging
biomarkers in published CTs in ophthalmology and an increase
in the use of imaging biomarkers for patient selection and
stratification and as secondary surrogate endpoints. Additional
efforts are needed to improve validation of these tools to
overcome infrastructural, economic, and cultural obstacles,29
optimizing the use of imaging biomarkers in clinical research
and allowing more frequent use of imaging surrogate primary
endpoints to support new drug development and approval.
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